Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease.
OBJECTIVE
Two multicentre, randomized, double-blind, placebo-controlled Phase II studies assessed the safety and efficacy of the oral protease-activated receptor 1 (PAR-1) antagonist E5555 in addition to standard therapy in Japanese patients with acute coronary syndrome (ACS) or high-risk coronary artery disease (CAD).


RESULTS
Patients with ACS (n = 241) or high-risk CAD (n = 263) received E5555 (50, 100, or 200 mg) or placebo once daily for 12 (ACS patients) or 24 weeks (CAD patients). The incidence of TIMI major, minor, and minimal bleeds requiring medical attention was similar in the placebo and combined E5555 (atopaxar) groups (ACS: 6.6% placebo vs. 5.0% E5555; CAD: 1.5% placebo vs. 1.5% E5555). There were no TIMI major bleeds and three CURE major bleeds (two with placebo; one with 100 mg E5555). There was a numerical increase in 'any' TIMI bleeding with the E5555 200 mg dose (ACS: 16.4% placebo vs. 23.0% E5555, P = 0.398; CAD: 4.5% placebo vs. 13.2% E5555, P = 0.081). The rate of major cardiovascular adverse events in the combined E5555 group was not different from placebo (ACS: 6.6% placebo vs. 5.0% E5555, P = 0.73; CAD: 4.5% placebo vs. 1.0% E5555, P = 0.066). There was a statistically significant dose-dependent increase in liver function abnormalities and QTcF with E5555. At trough dosing levels in both populations, mean inhibition of platelet aggregation was > 90% with 100 and 200 mg E5555, and 20-60% with 50 mg E5555.


CONCLUSIONS
E5555 (50, 100, and 200 mg) did not increase clinically significant bleeding, although there was a higher rate of any TIMI bleeding with the highest two doses. All doses tested achieved a significant level of platelet inhibition. There was a significant dose-dependent increase in liver function abnormalities and QTcF. Although further study is needed, PAR-1 antagonism may have the potential to be a novel pathway for platelet inhibition to add on to the current standard of care therapy.
Goto
Shinya
S
Department of Medicine (Cardiology), Tokai University School of Medicine, Isehara, Kanagawa 259-1143, Japan. shinichi@is.icc.u-tokai.ac.jp
Ogawa
Hisao
H
Takeuchi
Masaru
M
Flather
Marcus D
MD
Bhatt
Deepak L
DL
D054058:Acute Coronary Syndrome / Q000188:drug therapy*; D000284:Administration, Oral; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology; D003324:Coronary Artery Disease / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D007097:Imines / Q000008:administration & dosage*; D008133:Long QT Syndrome / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*; D011725:Pyridines / Q000008:administration & dosage*
C540445:E 5555; D007097:Imines; D010975:Platelet Aggregation Inhibitors; D011725:Pyridines
N Engl J Med. 2001 Aug 16;345(7):494-502
11519503
Am J Cardiol. 2009 Feb 2;103(3 Suppl):4A-10A
19166707
Eur Heart J. 2010 Jan;31(1):17-28
19948715
Curr Med Chem Cardiovasc Hematol Agents. 2004 Apr;2(2):149-56
15320797
Expert Opin Ther Pat. 2006 Apr;16(4):493-505
20144050
Ann Intern Med. 1991 Aug 15;115(4):256-65
1906692
Stroke. 2003 Oct;34(10):2349-54
12958323
Circ J. 2007 Jul;71(7):995-1003
17587702
Eur Heart J. 2000 Dec;21(24):2033-41
11102254
Lancet. 2009 Mar 14;373(9667):919-28
19286091
Thromb Haemost. 2009 Jul;102(1):111-9
19572075
Nature. 2000 Sep 14;407(6801):258-64
11001069
Blood Rev. 2009 Mar;23(2):61-5
18644663
Circulation. 2000 Mar 14;101(10):1206-18
10715270
J Thromb Haemost. 2005 Oct;3(10):2315-23
16194207
N Engl J Med. 2009 Sep 17;361(12):1139-51
19717844
JAMA. 2006 Jan 11;295(2):180-9
16403930
N Engl J Med. 2009 Sep 10;361(11):1045-57
19717846
J Atheroscler Thromb. 2010 Feb 26;17(2):156-64
20124733
N Engl J Med. 2007 Nov 15;357(20):2078-81
17982183
Circ J. 2005 Jul;69(7):767-73
15988100
J Thromb Haemost. 2006 Jan;4(1):114-20
16409460
Thromb Res. 2010 Mar;125(3):257-61
19476974
Circ Res. 2007 May 11;100(9):1261-75
17495233
Circulation. 2006 May 16;113(19):2363-72
16702489
Circulation. 2007 Aug 14;116(7):e148-304
17679616
N Engl J Med. 2007 Nov 15;357(20):2001-15
17982182
Hepatology. 2004 Feb;39(2):574-8
14768020
JAMA. 2007 Mar 21;297(11):1197-206
17374814
J Invasive Cardiol. 2003 Mar;15 Suppl B:3B-9B; discussion 9B-10B
12724580